Login to Your Account

Arrowhead Research's ARC-520 shows promise in phase IIa hepatitis B study

By Michael Fitzhugh
Staff Writer

Thursday, September 24, 2015

Arrowhead Research Corp. reported new top-line data on its lead RNAi therapy ARC-520, demonstrating that it achieved significant hepatitis B virus (HBV) surface antigen reductions during a phase IIa study, particularly in treatment-naïve patients who tested positive for HBV e-antigen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription